March 23, 2016
FDA Approved Cinqair (reslizumab) To Treat Severe Asthma
The U.S. Food and Drug Administration has approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.
This important regulatory milestone has historical, early-stage development ties to NeXeption. Ception Therapeutics, Inc., formed by Nexeption in 2005 around this compound, acquired the rights to reslizumab recognizing the drug’s potential and believed that it would be efficacious if studied in the correct disease states where eosinophils were the driver of disease. Ception raised an initial $77 million of venture capital funding and successfully completed a proof of concept study in eosinophilic asthma. In 2010, based on Phase II results, Ception was acquired by Cephalon, which was later acquired by Teva Pharmaceuticals in 2011.
The NeXeption team is proud to have advanced the early development of this medicine that is now approved by the FDA and available to patients.
*See Cinqair full prescribing information.
Link to FDA Release: